Acadia Pharmaceuticals reported $2.93B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
ALKERMES USD 7.43B 629M Nov/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Cara Therapeutics USD 30M 336M Mar/2026
Corcept Therapeutics USD 7.63B 4.83B Nov/2026
Cytokinetics USD 7.51B 1.66B Nov/2026
Eisai JPY 1.49T 73.62B Nov/2026
Eli Lilly USD 1.09T 40.33B Sep/2026
Incyte USD 24.6B 1.95B Sep/2026
J&J USD 653.61B 42.25B Sep/2026
Moderna USD 99.14B 22.26B Nov/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Pfizer USD 165.12B 1.71B Nov/2026
Prothena USD 437M 76M Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026